Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 8Recruiting 5Active not recruiting 4Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Pancreatic Neoplasms 23Breast Neoplasms 13Triple Negative Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 3Thymoma 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Nasopharyngeal Carcinoma 2Locally Advanced Pancreatic Cancer 2Borderline Resectable Pancreatic Cancer 2Biliary Tract Neoplasms 2Advanced Pancreatic Cancer 2Advanced Gastric Cancer 2Uterine Cervical Neoplasms 1Thromboembolism 1Thoracic Neoplasms 1Stage IV Gastric Cancer With Metastasis 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Lung 1Small Cell Lung Carcinoma 1Resectable Biliary Tract Cancer 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Muscle-Invasive Bladder Carcinoma 1Melanoma 1Lung Diseases 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Locally Advanced Cervical Carcinoma 1

Interventions

Cisplatin 22Radiotherapy 15Cetuximab 12Docetaxel 11Carboplatin 10pembrolizumab 8toripalimab 6camrelizumab 6Paclitaxel 5Nivolumab 5Neoadjuvant Therapy 5Fluorouracil 5Drug Therapy 5Chemoradiotherapy 5nimotuzumab 4durvalumab 4sintilimab 3cemiplimab 3apatinib 3advexin 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Immunohistochemistry 3Celecoxib 3Blood Specimen Collection 3nedaplatin 2Therapeutics 2Tegafur 2Radiotherapy, Intensity-Modulated 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Squamous Cell Carcinoma of Head and Neck × 130-nm albumin-bound paclitaxel × Clear all
NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Tongji Hospital

Phase 2 Unknown
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Sun Yat-sen University

Phase 2 Unknown
53 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡